BCR and chronic myelogenous leukemia, BCR-ABL1 positive: However, after a thorough discussion with hemato‐histopathologists and senior hematologists in a multidisciplinary team (MDT) meeting, he was commenced earlier on TKI (Tyrosine kinase inhibitor therapy) as the majority of cells were suggestive of CML with BCR ABL1 fusion gene. Cytoreduction therapy with hydroxyurea and Dasatnib was started.